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Abstract The molecular events whereby gastrin occupancy of
G/CCKB receptors leads to phosphatidylinositol (PI) 3-kinase
activation have been examined. We report here that this peptide
promotes the association between two non-receptor tyrosine
kinases, p60Src and p125FAK, and elicits a parallel increase in
tyrosine phosphorylation and activity of both kinases. Gastrin-
induced PI 3-kinase activity was coprecipitated with p60Src and
p125FAK and was inhibited by herbimycin A, the selective Src
inhibitor PP-2 or cytochalasin D, which disrupts the actin
cytoskeleton and prevents p125FAK activity. These results
indicate, for the first time, that a p60Src/p125FAK complex acts
upstream of the gastrin-stimulated PI 3-kinase pathway.
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1. Introduction
Although characterized as a stimulant of gastric acid secre-
tion, the peptide hormone gastrin exerts growth-promoting
e¡ects on normal and neoplastic gastrointestinal tissues.
This regulatory peptide has been reported to stimulate the
growth of normal gastrointestinal mucosa [1]. It also induces
the proliferation of colon, gastric and pancreatic cancer cell
lines established in vitro [2^4], as well as tumor cells trans-
planted in vivo [5]. These e¡ects have been shown to be medi-
ated by a speci¢c transmembrane G protein-coupled receptor,
the G/CCKB receptor, which is known to be linked to the
phospholipase C/protein kinase C pathway [4,6]. Like many
growth factors involved in cell proliferation, gastrin activates
the mitogen-activated protein kinases (MAPK) cascade [7,8]
and enhances subsequently the expression of early genes
known to function in regulating cell growth, such as the pro-
to-oncogenes c-fos or c-jun [9]. Phosphatidylinositol 3-kinases
(PI 3-kinases), lipid kinases which catalyze the 3P-phospho-
rylation of inositol phospholipids, are known to play an im-
portant role in mitogenesis. This family of kinases is activated
by a variety of cell receptors. Receptors with intrinsic tyrosine
kinase activity recruit heterodimeric PI 3-kinase consisting of
a 110-kDa catalytic subunit (p110) and an 85-kDa regulatory
subunit (p85). Activation of PI 3-kinase by tyrosine kinase
receptors, such as platelet-derived growth factor receptor or
epidermal growth factor receptor, is well documented and is
mediated by binding of autophosphorylated tyrosine residues
of the tyrosine kinases receptors to the SH2 (for Src homol-
ogy 2) domain of p85 [10,11]. In contrast, the mechanism
leading to PI 3-kinase activation by insulin [12] or insulin-
like growth factor I [13] involves the phosphorylation of an
intermediate protein, the insulin receptor substrate-1 (IRS-1),
which then associates the SH2 domain of p85. In addition to
the tyrosine phosphorylation-dependent activation of PI 3-
kinase, it has been reported that the LQ subunits of G proteins
also stimulate the lipid kinase activity of a novel PI 3-kinase
that do not interact with p85, designated p110Q [14]. Only few
ligands acting via G protein-coupled receptors, such as angio-
tensin or noradrenaline, have been shown to increase the ac-
tivity of the p85/p110 PI 3-kinase [15,16]. We have recently
demonstrated that gastrin induced PI 3-kinase activity in anti-
p85 precipitates [17]. However, the mechanism leading to the
activation of the classical p85/p110 form of PI 3-kinase by
seven transmembrane spanning receptors is still poorly de-
¢ned. Tyrosine phosphorylation has been involved in the in-
tracellular signaling of peptides that act as potent growth
factors through G protein-coupled receptors. Since the G/
CCKB receptor does not possess intrinsic tyrosine kinase ac-
tivity, the tyrosine phosphorylations induced by gastrin could
be mediated by activation of one or more non-receptor tyro-
sine kinases. Several lines of evidence suggest a role for the
ubiquitous non-receptor Src-family tyrosine kinases in signal
transduction leading to cell proliferation via G protein-
coupled receptors. Indeed, inhibition of Src-related kinases
has been shown to block angiotensin II-stimulated Ras acti-
vation [18] as well as lysophosphatidic acid and K2 adrenergic
receptor-stimulated MAPK pathway [19]. The catalytic activ-
ity of p60Src is tightly regulated in vivo by phosphorylation:
phosphorylation of tyrosine 527 in the C-terminal tail is in-
hibitory whereas the kinase domain phosphorylation (at tyro-
sine 416) is stimulatory [20]. Although it is known that gastrin
stimulates the phosphorylation of Src-family kinases [21,22],
whether this peptide activates or not p60Src has not yet been
established.
Since we have previously reported that gastrin exerts troph-
ic e¡ects on the tumor-derived pancreatic acinar cell line
AR4-2J [4], we analyzed, in this cellular model, the possibility
that this peptide might stimulate the activity and the associa-
tion of p60Src with another cytosolic tyrosine kinase, the focal
adhesion kinase (p125FAK). P125FAK is phosphorylated on ty-
rosine residues following activation by integrins and onco-
genes [23], addition of growth factors [24] or stimulation by
neuropeptides, such as bombesin, vasopressin or gastrin
[6,25]. We also assessed the role of the p60Src/p125FAK com-
plex in the gastrin-stimulated PI 3-kinase signaling pathway.
2. Materials and methods
2.1. Cell culture
AR4-2J cells, originally obtained by Jessop and Hay [26] from a rat
exocrine pancreatic tumor (azaserine induced), were a gift from Dr. C.
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Logsdon (Ann Arbor, MI). The cells, plated at 75 000 cells/ml, were
grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM), supple-
mented with 10% fetal calf serum. The medium was changed every
2 days.
2.2. Immunoprecipitation
AR4-2J cells were serum starved in DMEM for 18 h before peptide
addition. After stimulation, the cells were washed with ice cold bu¡er
A (50 mM HEPES, 150 mM NaCl, 10 mM EDTA, 10 mM Na4P2O7,
100 mM NaF, 2 mM orthovanadate, pH 7.5) and homogenized in 500
Wl lysis bu¡er (bu¡er A containing 1% Triton X-100 or 1% NP-40 for
kinase activities, 0.5 mM phenylsulfonyl £uoride, 20 WM leupeptin,
100 IU/ml trasylol) for 15 min at 4‡C. The solubilizates were immu-
noprecipitated with the indicated antibodies preadsorbed on protein-
A or protein-G Sepharose.
2.3. Western blotting analysis
Immunoprecipitates were washed twice with 30 mM HEPES, pH
7.5 containing 30 mM NaCl and 0.1% Triton X-100, resuspended in
SDS sample bu¡er and boiled for 5 min. Proteins were separated by
SDS-PAGE and transferred to polyvinylidene di£uoride (PVDF)
membranes (Immobilon PVDF Millipore). Membranes were blocked
with saline bu¡er (10 mM Tris, 140 mM NaCl, pH 7.4) containing 5%
bovine serum albumin (BSA) or non-fat dried milk and incubated
overnight with the indicated antibodies. Proteins were visualized using
125I-protein-A followed by autoradiography.
2.4. Immune complex kinase assays
Immunoprecipitates were washed twice with lysis bu¡er and four
times with TBS (25 mM Tris, pH 7.5, 150 mM NaCl). Kinase assays
were carried out at 30‡C for 10 min in 40 Wl of kinase bu¡er (20 mM
HEPES, pH 7.5, 10 mM MnCl2, 1 mM dithiothreitol, 3.75 WM cold
ATP, 5^10 WCi of [Q-32P]ATP). In Src-kinase assays, 5 WM of enolase
was added as an exogenous substrate. Samples were analyzed by SDS-
PAGE under reducing conditions. The gels were then treated with 1 N
KOH at 60‡C for 1 h after electrophoresis and autoradiographed.
2.5. PI 3-kinase assay
After immunoprecipitation with the indicated antibodies, the pellets
were assayed for the PI 3-kinase activity. After washing, the pellets
were resuspended in 30 Wl 20 mM HEPES, 0.4 mM EDTA, 0.4 mM
Na2HPO4. The kinase reaction was started by addition of phospha-
tidylinositol (PtdIns) at a ¢nal concentration of 0.2 mg/ml, 10 mM
MgCl2 and 50 WM [Q-32P]ATP. After 15 min, the reaction was stopped
by addition of 4 M HCl and the phosphoinositol lipids were extracted
with chloroform/methanol (1:1). Phospholipids contained in the or-
ganic phase were separated by thin layer chromatography. The plate
was analyzed by autoradiography.
2.6. Materials
Human gastrin2ÿ17ns was purchased from Bachem (Switzerland).
125I-Na (100 mCi/ml) was obtained from Amersham and [Q-32P]ATP
(7000 Ci/mmol) from ICN (France). PtdIns from bovine liver, cyto-
chalasin D, enolase and wortmannin were purchased from Sigma
(France). Herbimycin A, PP-2 and LY294002 were from Calbiochem
(France). Anti-p125FAK and anti-phosphotyrosine antibodies were
from Santa Cruz (Tebu, France). Monoclonal anti-p60Src antibodies
were obtained from Oncogene Science (Genzyme, France). Rabbit
polyclonal antibodies speci¢c to p85 were kindly provided by Drs.
Y. Le Marchand-Brustel and J.F. Tanti (INSERM U.145, Nice,
France).
3. Results
3.1. Tyrosine phosphorylation of p60Src and p125FAK in
response to gastrin
We ¢rst investigated whether gastrin could induce tyrosine
phosphorylation of p60Src and p125FAK in pancreatic tumor
cells. AR4-2J cells were stimulated with 10 nM gastrin for
varying lengths of time (Fig. 1). Cell lysates were subjected
to immunoprecipitation with anti-p60Src (A) or anti-phospho-
tyrosine (B) antibodies and precipitates were analyzed by im-
munoblotting using anti-phosphotyrosine (A) or anti-p125FAK
(B) antibodies. An increase in tyrosine phosphorylation of
both p60Src and p125FAK was detected within 1 min and
reached a maximum at 3 min (p60Src : 2.53-fold þ 0.2,
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Fig. 1. Tyrosine phosphorylation of p60Src and p125FAK in response
to gastrin. AR4-2J cells were incubated for the times indicated with
10 nM of gastrin. Cellular proteins were immunoprecipitated (IP)
with (A) anti-p60Src or (B) anti-phosphotyrosine (Py) antibodies and
immunoprecipitates were immunoblotted (IB) with (A) anti-phos-
photyrosine or (B) anti-p125FAK antibodies. The migration of phos-
phorylated p60Src and p125FAK is indicated by the arrow. The data
presented are representative of three independent experiments with
similar results.
Fig. 2. Gastrin induces association of p60Src with p125FAK. AR4-2J
cells were stimulated for the indicated time periods with 10 nM gas-
trin. A: Cell extracts were immunoprecipitated (IP) with an anti-
body to p60Src and immunoblotted (IB) using anti-p125FAK antibod-
ies. The migration of p125FAK is indicated by the arrow. B: Cellular
proteins were immunoprecipitated (IP) with an anti-p125FAK anti-
body and immunoprecipitates were immunoblotted (IB) with an
anti-p60Src antibody. The association between p60Src and p125FAK is
indicated by the arrow. Similar results were obtained in three inde-
pendent experiments.
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p125FAK : 2.0-fold þ 0.2, n = 3). The magnitude of tyrosine
phosphorylation of p60Src decreased after 3 min, whereas
for p125FAK it remained stable until 5 min.
3.2. Gastrin induces association of p60Src with p125FAK
To determine whether p125FAK associates p60Src following
gastrin stimulation, immunoprecipitates from AR4-2J cell ly-
sates obtained with an anti-p60Src antibody were immunoblot-
ted with an anti-p125FAK antibody (Fig. 2A). The amount of a
125-kDa protein recognized by anti-p125FAK antibody was
increased in the anti-p60Src precipitates after gastrin stimula-
tion. The association between p60Src and p125FAK reached a
maximum at 1 min (3.4-fold þ 0.1, n = 3) and decreased there-
after. This association was also con¢rmed by immunoblot
using an anti-p60Src antibody in anti-p125FAK immunoprecip-
itates (Fig. 2B).
3.3. Activation of p60Src and p125FAK tyrosine kinases by
gastrin
We then examined the ability of gastrin to regulate kinase
activity of p60Src in AR4-2J cells. Src kinase assays were per-
formed in anti-p60Src immunoprecipitates after treatment of
the cells with 10 nM of gastrin (as described in Section 2). The
phosphorylation of the exogenous substrate enolase was
measured. The p60Src kinase activation by gastrin was in-
creased within 30 s, reached a peak value at 1 min (2.2-fold
þ 0.2, n = 3) and decreased thereafter (Fig. 3A). Kinase activ-
ity of p125FAK has been shown to correlate with its phospho-
rylation. Since gastrin increased tyrosine phosphorylation of
this protein, we examined whether activation of p125FAK was
detected following gastrin stimulation. In vitro autophosphor-
ylation assays were carried out on anti-p125FAK immunopre-
cipitates. As shown in Fig. 3B, we observed a rapid and tran-
sient increase (maximum at 1 min: 2.5-fold þ 0.4, n = 3) in
p125FAK activity. The rapid kinetics of p60Src and p125FAK
activation could be correlated to the phosphorylation of
both proteins in response to gastrin.
3.4. Activation of PI 3-kinase in anti-p60Src and anti-p125FAK
precipitates following gastrin stimulation
We have recently demonstrated that gastrin activates the PI
3-kinase in AR4-2J cells [17]. To go further into the mecha-
nism that relay the signal from the G/CCKB receptor to this
enzyme, we examined whether PI 3-kinase activity was de-
tected in association with p60Src after gastrin stimulation. PI
3-kinase activity was measured in anti-p60Src immunoprecipi-
tates from cells treated with 10 nM of gastrin (Fig. 4A). The
activation reached a maximum 1 min (3.0-fold þ 0.4, n = 3)
after peptide addition. We also analyzed the possibility that
p125FAK could play a role in the PI 3-kinase pathway induced
by gastrin. PI 3-kinase assays were performed in anti-p125FAK
precipitates from gastrin-treated AR4-2J cells. An increase in
PI 3-kinase activity was detectable at 30 s (Fig. 4B). The
stimulation reached a peak value within 3 min of treatment
(3.1-fold þ 0.7, n = 3) and decreased at 5 min. Thus, a time-
dependent increase in PI 3-kinase activity was observed in
anti-p60Src and anti-p125FAK precipitates after gastrin stimu-
lation, suggesting that p60Src and p125FAK are potentials me-
diators of PI 3-kinase activation by gastrin.
3.5. p60Src and p125FAK act upstream of PI 3-kinase activation
by gastrin
To determine the contribution of Src-family tyrosine kin-
ases in the PI 3-kinase activation induced by gastrin, we ex-
amined the e¡ect of herbimycin A or the novel speci¢c Src-
protein tyrosine kinase inhibitor PP-2 [27]. Preincubation of
the cells with 1 WM of herbimycin A or 50 WM of PP-2 re-
spectively diminished by 91% þ 1 and 102% þ 1 (n = 3) the PI
3-kinase activity in anti-p85 precipitates (Fig. 5A), con¢rming
the role of Src-related kinases in this signaling cascade. The
speci¢city of herbimycin A or PP-2 was assessed in vitro. Both
inhibitors completely abolished basal and gastrin-stimulated
p60Src kinase activity (Fig. 5B, left) without a¡ecting the au-
tophosphorylation of p125FAK (data not shown). We then
determined the e¡ect of cytochalasin D, known to depolymer-
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Fig. 3. Activation of p60Src and p125FAK tyrosine kinases by gastrin.
AR4-2J cells were stimulated with 10 nM gastrin for varying lenghts
of time. A: P60Src was immunoprecipitated (IP) with a speci¢c anti-
p60Src antibody and its kinase activity was assayed as described in
Section 2. The arrow indicates the phosphorylated exogenous sub-
strate enolase. B: P125FAK activity was measured in anti-p125FAK
immunoprecipitates as described in Section 2. The autophosphoryla-
tion of p125FAK protein is indicated by the arrow. The data pre-
sented are representative of three independent experiments with sim-
ilar results.
Fig. 4. Involvement of p60Src and p125FAK in gastrin-induced PI 3-
kinase activation. AR4-2J cells were treated for the times indicated
with 10 nM gastrin. Cell lysates were immunoprecipitated (IP) with
an antibody against p60Src (A) or p125FAK (B). Immunoprecipitates
were assayed for PI 3-kinase activity using PtdIns as substrate. The
phospholipids were resolved on thin layer chromatography plates.
The arrow indicates the phosphorylated substrate, PtdIns-P (PIP).
Similar results were obtained in three independent experiments.
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ize the actin cytoskeleton and prevent the activation of
p125FAK by neuropeptides [28,29]. Pretreatment of cells with
2.5 WM of cytochalasin D blocked p125FAK autophosphoryla-
tion (Fig. 5B, right) and greatly diminished PI 3-kinase activ-
ity (88% þ 4, n = 3) assessed in anti-p85 precipitates in re-
sponse to gastrin (Fig. 5A).
To support the conclusion that p60Src and p125FAK are up-
stream of PI 3-kinase activation rather than in a downstream
pathway, we examined the e¡ects of two commonly used PI 3-
kinase inhibitors, wortmannin and LY294002, on p60Src and
p125FAK activation stimulated by gastrin. We did not ob-
served any inhibition of gastrin-induced tyrosine kinase activ-
ities in cells pretreated with wortmannin or LY294002 (Fig.
5D) at drug concentrations (10 nM and 10 WM respectively)
which totally abolish the activation of the PI 3-kinase by
gastrin (Fig. 5C).
4. Discussion
G protein-coupled receptors have been shown to mediate
rapid tyrosine phosphorylations of several proteins that par-
ticipate in mitogenic signal transduction. Since these receptors
lack intrinsic tyrosine kinase activity, recruitment of non-re-
ceptor tyrosine kinases might play an important role in G
protein-coupled receptor signaling. Several reports describe
the implication of candidate tyrosine kinases linking this class
of receptors to the Ras/MAPK cascade, a pathway known to
be involved in cell proliferation. These include proto-onco-
genes like p60Src and Src-family kinases such as Fyn, Lyn
and Yes or the more distantly related Syk [30,31]. Inhibitors
of Src-related kinases or transfection of cells with Csk (for C-
terminal Src kinase), a negative regulator of Src, demonstrate
that Src-like kinases link the LQ subunit of the heterotrimeric
G protein to activation of the MAPK pathway through phos-
phorylation of Shc and the recruitment of Grb2 and Sos [19].
In addition, p125FAK and the novel Ca2- and PKC-depend-
ent protein tyrosine kinase PYK2 [32] de¢ne a new subfamily
of non-receptor tyrosine kinases which can also be activated
by neuropeptides [25]. PYK2 can acts to link Gi and Gq-
coupled receptors with Grb2 and Sos to activate the MAPK
signaling pathway [33]. Although it is becoming increasingly
clear that a number of non-receptor tyrosine kinases can act
upstream of the Ras/MAPK cascade, the contribution of these
kinases to the activation of the PI 3-kinase pathway by G
protein-coupled receptors is still poorly understood. Since
we have recently reported that gastrin stimulates the p85/
p110 PI 3-kinase in AR4-2J cells [17], we undertook the
present study to further characterize the upstream events
that can link the G/CCKB receptor to the PI 3-kinase.
In the ¢rst part of this work, we demonstrate that gastrin
potently stimulates the enzymatic activity of p60Src and
p125FAK. This activation is in accordance with enhanced
phosphorylation of these proteins by this peptide. In addition,
we have shown an association of p60Src with p125FAK upon
gastrin stimulation. This interaction might regulate p60Src
and/or p125FAK activities. In the second part of this work,
we have examined the involvement of these two tyrosine kin-
ases in the PI 3-kinase pathway induced by gastrin. We have
detected an increased PI 3-kinase activity in anti-p60Src and
anti-p125FAK precipitates in response to gastrin, with kinetics
correlated to those observed for the activation of p60Src and
p125FAK. Inhibitors of Src kinases family members, herbimy-
cin A or the more recent and speci¢c PP-2 [27], greatly dimin-
ishes PI 3-kinase activity, at drug concentrations similar to
those reported to inhibit activation of these enzymes by other
growth factors [34,35], suggesting that p60Src could lie up-
stream of the PI 3-kinase in gastrin-treated cells. Agonist-
mediated increase in p125FAK activation has been previously
shown to be accompanied by profound alterations in the or-
ganization of the actin cytoskeleton and in the assembly of
focal adhesions, the areas of the plasma membrane where
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Fig. 5. p60Src and p125FAK act upstream of PI 3-kinase activation
by gastrin. A: AR4-2J cell lysates were pretreated with the vehicle,
1 WM herbimycin A for 24 h, 50 WM PP-2 for 30 min or 2.5 WM
cytochalasin D for 2 h in the absence (black bars) or presence
(hatched bars) of 10 nM gastrin. PI 3-kinase activity was measured
in anti-p85 immunoprecipitates using PtdIns as substrate. The data
were plotted as percentages of the control values. Data from three
separate experiments are presented as means þ S.E.M. (bars). B:
Left: AR4-2J cells were stimulated with 10 nM gastrin; p60Src was
immunoprecipitated and in vitro kinase reactions were performed in
presence or absence of 1 WM herbimycin A or 1 WM PP-2. Right:
Cells were pretreated with 2.5 WM cytochalasin D for 2 h and then
treated with 10 nM gastrin. The extracts were immunoprecipitated
with an anti-p125FAK antibody and in vitro kinase reactions were
carried out as described in Section 2. C: AR4-2J cell lysates were
pretreated with the vehicle, 10 nM wortmannin or 10 WM
LY294002 for 1 h, in the presence or not of 10 nM gastrin. PI 3-
kinase activity was measured in anti-p85 immunoprecipitates using
PtdIns as substrate. The phospholipids were resolved on thin layer
chromatography plates. The arrow indicates the phosphorylated
substrate, PtdIns-P (PIP). D: AR4-2J cell lysates were pretreated
with the vehicle, 10 nM wortmannin or 10 WM LY294002 for 1 h,
in the presence or not of 10 nM gastrin. The extracts were immuno-
precipitated with an anti-p60Src or an anti-p125FAK antibody and in
vitro kinase reactions were carried out as described in Section 2.
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p125FAK is localized [24,36,37]. In the present study, we also
demonstrate that cytochalasin D, which disrupts the network
of actin micro¢laments, prevents autophosphorylation of
p125FAK and decreases the activity of the PI 3-kinase by gas-
trin. Thus, we identi¢ed a gastrin-dependent PI 3-kinase path-
way that requires the integrity of the actin cytoskeleton and
the activation of p125FAK and p60Src. In addition, p125FAK
and p60Src were not blocked by PI 3-kinase inhibitors, sup-
porting the conclusion that both kinases act upstream of PI 3-
kinase rather than in a downstream pathway.
In summary, our results demonstrate for the ¢rst time that
activation of a p60Src/p125FAK complex, that might be respon-
sible for the proliferative e¡ects of gastrin, is one mechanism
by which the G protein-coupled receptor G/CCKB stimulates
the PI 3-kinase pathway.
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